pharmaceutical litigation Pharmaceutical

It’s a common enough occurrence – a talented young athlete sidelined with an injury. A shoulder or knee has taken a bit too much of a beating, and doesn’t respond to the usual rehab. A conference among coaches, doctors, the athlete, and his family results in a decision that surgery is the best solution. But, strangely, as the athlete works to recover after the surgery, problems persist, and worsen. In a terrible twist, a medical device originally intended to speed healing and lessen pain during recovery – a pain pump – has caused a serious, permanent injury. Patients rely on being able to trust the information provided to them by the makers of these “miracle” drugs and devices. They expect that products have been properly tested and have passed all types of screenings to make sure they are safe. Unfortunately, this is often not true. For some companies, the priority changes from patient health to their bottom line, and they are slow to admit a device or drug is defective or dangerous.

The attorneys in our Mass Torts section are honored to represent individuals harmed by the pharmaceutical and medical device industry, and to be among a small group of trial lawyers that are willing to play the role of David against these Goliaths.

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.


back to top